MeSH D012208 - rhabdomyosarcoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Meitheal Pharmaceuticals | Dactinomycin | Dactinomycin |  | 2020-11-13 |  |  |
| Melphalan | Melphalan |  | 2021-05-28 |  |  | |
| Etoposide | Etoposide |  | 1996-07-24 |  |  | |
| Teva | Etoposide | Etoposide |  | 1994-02-10 |  |  |
| Cyclophosphamide | Neosar |  | 1993-04-29 |  |  | |
| Etoposide | Toposar |  | 1995-02-27 |  |  | |
| Vincristine | Vincasar |  | 1987-07-17 |  |  | |
| Vincristine | Vincristine |  | 1999-09-01 |  |  | |
| Dr Reddys Laboratories | Cyclophosphamide | Cyclophosphamide | 2036-02-15 | 2020-07-30 |  |  |
| Melphalan | Melphalan |  | 2017-12-08 |  |  | |
| Ingenus | Melphalan | Melphalan |  | 2020-02-18 |  |  |
| Mylan | Etoposide | Etoposide |  | 2001-09-19 |  |  |
| Melphalan | Melphalan |  | 2009-06-09 |  |  | |
| Cipla | Cyclophosphamide | Cyclophosphamide |  | 2019-01-18 |  |  |
| Eli Lilly | Vincristine | Oncovin |  | 1982-01-01 |  |  |
| Alembic Pharmaceuticals | Cyclophosphamide | Cyclophosphamide |  | 2022-11-10 |  |  |
| Apotex | Melphalan | Alkeran |  | 1982-01-01 |  |  |
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
63%35/56
Phase 2
26%22/85
Phase 3
40%12/30
Approved: 7Overall Success rate: 6%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use